News Headlines Article

FDA Again Fines American Red Cross for Blood Safety Lapses; This Time $16 Million
Health Leaders Media

The American Red Cross will have to pay $16.18 million in federal fines because of a failure to comply with safe practices dealing with collection and manufacturing of blood products, including red cells, plasma, and platelets, the U.S. Food and Drug Administration announced late yesterday. While there is no evidence the practices that resulted in the fines have endangered any patients who received blood products, the FDA said these regulatory violations “decrease the assurance that blood products manufactured by the American Red Cross will continue to be safe and have the potential to compromise the safety of the blood supply.”